Altimmune
$6.69
183
-$0.05-0.74% Wednesday 19:32
统计数据
当日最高
-
当日最低
-
52周最高
14.84
52周最低
2.09
成交量
1,873,127
平均成交量
5,066,104
市值
465.83M
市盈率
0
股息收益率
-
股息
-
股息
0%股息收益率
10年增长
N/A
5年增长
N/A
3年增长
N/A
1年增长
N/A
收益
27Mar已确认
预期每股收益
-0.43
实际每股收益
-0.33
人们还关注
此列表基于关注ALT的Stock Events用户的观察列表。这不是投资建议。
竞争者
这个列表是基于最近市场事件的分析。这不是投资建议。
Novavax
NVAX
市值1.78B
Moderna
MRNA
市值45.51B
BioNTech
BNTX
市值19.1B
Pfizer
PFE
市值158.55B
Johnson & Johnson
JNJ
市值351.76B
Inovio Pharmaceuticals
INO
市值209.36M
Dynavax Technologies
DVAX
市值1.47B
VBI Vaccines
VBIV
市值18.93M
GSK
GSK
市值79.79B
Sanofi
SNY
市值122.89B
分析师评级
18.8$平均价格目标
最高估值为 $25。
来自过去6个月内的 6 个评级。这不是投资建议。
买入
50%
持有
50%
卖出
0%
关于
Commercial Services
Miscellaneous Commercial Services
Manufacturing
Pharmaceutical Preparation Manufacturing
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Show more...
首席执行官
Vipin Garg
员工
59
国家
US
ISIN
US02155H2004
WKN
000A2N5Z6